Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors
about
Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transportersThe clinically relevant pharmacogenomic changes in acute myelogenous leukemiaMolecular pathology of lung cancer: key to personalized medicine.Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients.Identification and functional characterization of breast cancer resistance protein in human bronchial epithelial cells (Calu-3).Axitinib targeted cancer stemlike cells to enhance efficacy of chemotherapeutic drugs via inhibiting the drug transport function of ABCG2.Synthesis and quantitative structure-activity relationships of selective BCRP inhibitors.Role of hypoxia and glycolysis in the development of multi-drug resistance in human tumor cells and the establishment of an orthotopic multi-drug resistant tumor model in nude mice using hypoxic pre-conditioning.Tyrosine kinase inhibitors: Multi-targeted or single-targeted?Multi-modal strategies for overcoming tumor drug resistance: hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology.Multi-functional nanocarriers to overcome tumor drug resistanceBCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure.Reversing multidrug resistance by tyrosine kinase inhibitorsSunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.Blood-brain barrier remodeling during brain metastasis formation.Development of EGFR-targeted polymer blend nanocarriers for combination paclitaxel/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells.Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?EGF receptor-targeted therapy in non-small-cell lung cancer: role of germline polymorphisms in outcome and toxicity.ABCG2: recent discovery of potent and highly selective inhibitors.Drug interactions with phytotherapeutics in oncology.Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics.Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance.On the pharmacogenetics of non-small cell lung cancer treatment.Cancer Drug Resistance: A Brief Overview from a Genetic Viewpoint.Scaffold identification of a new class of potent and selective BCRP inhibitors.An outline of main factors of drug resistance influencing cancer therapy.Reversal of multidrug resistance in vitro and in vivo by 5-N-formylardeemin, a new ardeemin derivative.Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib.The Interface between BCR-ABL-Dependent and -Independent Resistance Signaling Pathways in Chronic Myeloid Leukemia.The potential of multi-compound nanoparticles to bypass drug resistance in cancer.Gout and hyperuricemia in Japan: perspectives for international research on purines and pyrimidines in man.Computational classification models for predicting the interaction of drugs with P-glycoprotein and breast cancer resistance protein.
P2860
Q24617999-FC3CD25D-8E46-4EE5-A14D-1252BA6686A3Q27014790-EEAA46E9-E482-4DA2-A44B-6187B876F472Q27691299-5E180F90-D615-42D8-9DB6-9CBDEA1A602CQ33410206-96E09AC5-3396-4522-A1A3-D1CACCDBB09DQ33506860-D5983650-4FEA-461D-A778-1DD5B2305BF3Q34253081-29C6D5AE-DE80-4878-B24F-DBAFC54BF111Q34476243-E2B9F235-5D4D-47B1-A291-54338D61426BQ34610733-7C8138A5-AB24-4A85-A565-61A19DA74CC5Q34983846-F17F092E-946C-4C55-9A71-FEF069739677Q35136562-D10903B5-989C-4471-9096-0430D732D499Q36980340-EE2E808D-F55E-4A2E-A059-52983DC8EFCFQ37135243-F243A297-AD7C-4649-A11D-E384CD75ECC5Q37183670-5F9ABB8A-A730-4F2C-9256-7B9F0F2E8B65Q37188016-96964F94-7210-4B31-AC5E-6EBDD8944A6CQ37217055-71CD5D0B-31C3-4A50-A8DB-9D37FCF5D6E5Q37280649-FE06CFCF-FDE3-4D37-8D7C-813A5A34BFF0Q37799220-6868F156-6D2B-454D-8594-AD738483BFFCQ37853578-C9DF36D1-6916-44EF-96D9-039E23F90AAAQ38034817-6514127E-2BA6-4C01-B2BB-0D42FC80341CQ38111799-6649B03F-AD44-44DB-9548-4F6356DC27C5Q38175476-349AC6C3-26BF-4995-8AA9-863BB936CF85Q38187646-3E83217B-D254-4D39-BEF0-E023E110B46AQ38246305-BE4DF024-CFDA-4246-9389-51DA6A337507Q38694947-7601F47E-00AB-4D51-A439-427CF3399F27Q38748101-05875D37-9445-42AE-BBBE-D8CA0E256809Q38904223-5A8627E2-2349-45E5-B9E9-0F8682187BFBQ38933079-B3A0AEE7-DDAF-4E90-A810-D43D12E533A2Q38991900-DC77A2C2-9C3B-4A72-9EBB-6B35001B203FQ39392579-75F51127-3163-4642-A709-52A4ADEEEBD7Q39874489-FE93E424-C6F8-420A-B4E8-3282C8466DE5Q41842515-471EF88B-0B1C-47B7-AD13-6B27FD0A8FEEQ47114290-D8F42CDD-D8E4-4C12-B501-1292C9FA0F91Q48530991-ED831EB3-5BE2-4648-B77E-7846F11CD20FQ51006060-7E33448E-E0E5-4D88-BF51-39D803D5D605
P2860
Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 February 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors
@en
Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors.
@nl
type
label
Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors
@en
Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors.
@nl
prefLabel
Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors
@en
Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors.
@nl
P2093
P2860
P921
P356
P1476
Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6604213
P407
P577
2008-02-05T00:00:00Z
2008-03-11T00:00:00Z